Production of recombinant biologics in plants has received considerable attention as an
alternative platform to traditional microbial and animal cell culture. Industrially relevant …

By the end of 2017, the Food and Drug Administration had approved a total of 77 therapeutic
monoclonal antibodies (mAbs), most of which are still manufactured today. Furthermore …

Biopharmaceutical protein production using transgenic plant cell bioreactor processes offers
advantages over microbial and mammalian cell culture platforms in its ability to produce …

Time to market, cost effectiveness, and flexibility are key issues in today's biopharmaceutical
market. Bioprocessing plants based on fully disposable, presterilized, and prevalidated …

Recombinant proteins have been produced for over 30 years. Applications range from
enzymes used in laundry detergents to antigen-detecting antibodies in cancer therapy …

Background The enzymatic conversion of lignocellulosic biomass into fermentable sugars is
a promising approach for producing renewable fuels and chemicals. However, the cost and …

Biocatalysis is an emerging area of technology, and to date few reports have documented
the economics of such processes. As it is a relatively new technology, many processes do …

This article documents the progress, cur-rent state, and projected future trends in titer and
yield as industrial and technological benchmarks for commercial-scale biopharmaceutical …

Enzymes are the complex protein moieties, catalyze the rate of chemical reactions by
transforming various substrates to specific products and play an integral part in multiple …

Biopharmaceutical Processing: Development, Design, and Implementation of Manufacturing
Processes covers bioprocessing from cell line development to bulk drug substances. The …